IDSA/AASLD Response to Cochrane Review on Direct-Acting Antivirals for Hepatitis C. - Suppr | 超能文献

IDSA/AASLD Response to Cochrane Review on Direct-Acting Antivirals for Hepatitis C.

作者信息

Powderly William G, Naggie Susanna, Kim Arthur Y, Vargas Hugo E, Chung Raymond T, Lok Anna S

机构信息

Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri.

Division of Infectious Diseases, Duke University School of Medicine, Durham, North Carolina.

出版信息

Clin Infect Dis. 2017 Nov 13;65(11):1773-1775. doi: 10.1093/cid/cix620.

DOI:10.1093/cid/cix620

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

IDSA/AASLD Response to Cochrane Review on Direct-Acting Antivirals for Hepatitis C.

Clin Infect Dis. 2017 Nov 13;65(11):1773-1775. doi: 10.1093/cid/cix620.

2

Immunosuppressive and antiviral treatment of hepatitis C virus-associated glomerular disease: A long-term follow-up.丙型肝炎病毒相关性肾小球疾病的免疫抑制和抗病毒治疗：长期随访

Int J Artif Organs. 2018 Jun;41(6):306-318. doi: 10.1177/0391398818762358. Epub 2018 Mar 29.

3

Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.直接作用抗病毒药物和宿主靶向药物时代的慢性丙型肝炎病毒感染的治疗。

J Infect. 2014 Jan;68(1):1-20. doi: 10.1016/j.jinf.2013.08.019. Epub 2013 Sep 4.

4

New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir.丙型肝炎治疗中的新型直接作用抗病毒药物：索磷布韦、来迪帕司韦、达卡他韦、西米普明、帕利瑞韦、奥比他韦和达沙布韦的综述

Expert Rev Clin Pharmacol. 2016;9(2):287-302. doi: 10.1586/17512433.2016.1129272. Epub 2016 Jan 8.

5

Response to Retreatment of hepatitis C virus Patients in whom Direct-Acting Antivirals have Failed.

Gastroenterol Hepatol. 2019 Nov;42(9):558-561. doi: 10.1016/j.gastrohep.2019.04.002. Epub 2019 Jul 15.

6

Hepatitis B virus reactivation after direct-acting antivirals for chronic hepatitis C infection.慢性丙型肝炎感染接受直接抗病毒药物治疗后出现的乙型肝炎病毒再激活

Lancet Gastroenterol Hepatol. 2018 Mar;3(3):145-147. doi: 10.1016/S2468-1253(18)30004-9. Epub 2018 Jan 19.

7

Review: In chronic hepatitis C virus infection, oral direct-acting antivirals have high sustained virologic response.综述：在慢性丙型肝炎病毒感染中，口服直接作用抗病毒药物具有较高的持续病毒学应答率。

Ann Intern Med. 2017 Jul 18;167(2):JC3. doi: 10.7326/ACPJC-2017-167-2-003.

8

Evaluation of Hepatitis C Patients in the Direct-Acting Antiviral Era.直接抗病毒药物时代丙型肝炎患者的评估

Clin Liver Dis. 2015 Nov;19(4):591-604, v. doi: 10.1016/j.cld.2015.06.001. Epub 2015 Aug 25.

9

Electrophysiological Adverse Effects of Direct-Acting Antivirals in Patients With Chronic Hepatitis C.直接作用抗病毒药物对慢性丙型肝炎患者的电生理不良影响

J Clin Pharmacol. 2017 Jul;57(7):931-932. doi: 10.1002/jcph.905. Epub 2017 May 3.

10

Letter: adoption of uniform nomenclature is crucial for estimating the true risk of HBV reactivation in patients treated with direct-acting antivirals for hepatitis C.信函：采用统一命名法对于评估接受丙型肝炎直接抗病毒药物治疗的患者中HBV再激活的真实风险至关重要。

Aliment Pharmacol Ther. 2018 Jun;47(11):1573-1574. doi: 10.1111/apt.14653.

引用本文的文献

1

Bad research is not all bad.坏的研究并非全是坏的。

Trials. 2023 Oct 20;24(1):680. doi: 10.1186/s13063-023-07706-1.

2

Life Expectancy of Insured People With and Without Hepatitis C Virus Infection, 2007-2017.2007 - 2017年丙型肝炎病毒感染患者与未感染患者的预期寿命

Open Forum Infect Dis. 2020 Feb 5;7(2):ofaa044. doi: 10.1093/ofid/ofaa044. eCollection 2020 Feb.